5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.98▲ | 3.00▼ | 3.00▼ | 3.12▼ | 3.30▼ |
MA10 | 2.99▼ | 3.01▼ | 3.02▼ | 3.22▼ | 3.41▼ |
MA20 | 3.00▼ | 3.03▼ | 3.08▼ | 3.38▼ | 3.30▼ |
MA50 | 3.01▼ | 3.13▼ | 3.17▼ | 3.50▼ | 3.22▼ |
MA100 | 3.03▼ | 3.19▼ | 3.31▼ | 3.29▼ | 3.41▼ |
MA200 | 3.11▼ | 3.34▼ | 3.42▼ | 3.19▼ | 4.44▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.002▼ | 0.001▲ | -0.005▼ | -0.043▼ | -0.042▼ |
RSI | 37.656▼ | 27.453▼ | 27.724▼ | 31.641▼ | 43.610▼ |
STOCH | 19.444▼ | 10.967▼ | 6.616▼ | 13.020▼ | 19.204▼ |
WILL %R | -85.714▼ | -96.000▼ | -97.222▼ | -99.306▼ | -99.519▼ |
CCI | -82.456 | -135.821▼ | -123.958▼ | -134.201▼ | -186.344▼ |
Tuesday, September 09, 2025 02:51 PM
Atea Pharmaceuticals, Inc. ( NASDAQ: AVIR) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:05 PM EDT ...
|
Monday, September 08, 2025 07:14 AM
If you have been tracking AAR (NYSE:AIR), you probably noticed the recent buzz after the company landed a major contract with the Defense Logistics Agency Troop Support. This $85 million opportunity ...
|
Tuesday, September 02, 2025 04:03 AM
BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
16/09/25 | 3.105 | 3.105 | 2.98 | 2.985 | 76,415 |
15/09/25 | 3.14 | 3.15 | 3.02 | 3.04 | 174,730 |
12/09/25 | 3.29 | 3.29 | 3.10 | 3.14 | 182,113 |
11/09/25 | 3.14 | 3.327 | 3.14 | 3.30 | 221,074 |
10/09/25 | 3.15 | 3.23 | 3.095 | 3.15 | 238,752 |
09/09/25 | 3.25 | 3.25 | 3.145 | 3.16 | 117,590 |
08/09/25 | 3.38 | 3.38 | 3.23 | 3.25 | 150,553 |
05/09/25 | 3.36 | 3.405 | 3.285 | 3.37 | 141,696 |
04/09/25 | 3.47 | 3.47 | 3.305 | 3.33 | 155,560 |
03/09/25 | 3.39 | 3.47 | 3.3695 | 3.46 | 159,476 |
|
|
||||
|
|
||||
|
|